Huang, Shu-WeiShu-WeiHuangSun, Ming-TsungMing-TsungSunLee, Wen-SenWen-SenLeeSu, Ying-ShihYing-ShihSuLee, Yi-TzuYi-TzuLeeChiang, Ming-HsienMing-HsienChiangWang, Yung-ChihYung-ChihWangYang, Ya-SungYa-SungYangTzeng, Shian-ChiuanShian-ChiuanTzengWu, Tien-YuanTien-YuanWuSun, Jui-ShengJui-ShengSunLin, Feng-HueiFeng-HueiLin2023-02-092023-02-092022-021684-1182https://scholars.lib.ntu.edu.tw/handle/123456789/627856Tigecycline is an antibiotic that well tolerated for treating complicated infections. It has received attention as an anti-cancer agent and expected to solve two major obstacles, sides effects that accompany chemotherapy and drug resistance, in the breast cancer treatment. However, previous studies reported that the levels in the blood are typically low of tigecycline, so higher doses are needed to treat cancer, that may increase the risk of side effects. To achieve better anti-cancer effects for tigecycline, we need to find a novel adjunct agent.enBreast cancer; Combination therapy; Pyrvinium pamoate; Tigecyclinejournal article10.1016/j.jmii.2020.12.008336105082-s2.0-85101357908WOS:000760190100007https://scholars.lib.ntu.edu.tw/handle/123456789/577140